Background
Autoimmune encephalitis is an inflammatory disorder of the brain that can be associated with different neuronal antibodies. Recently, an increasing number of autoantibodies have been identified, including GABA A R antibodies, which appear to be associated with a severe form of encephalitis with refractory status epilepticus [1] .
Here is a report on a patient with encephalitis associated with GAD65 and GABA A R antibodies who manifests an unanticipated clinical presentation. The longitudinal follow-up is described.
Case report
A 38-year-old female presented with sudden onset of dysgueusia (as ''taste of corpse'' that sometimes led to vomiting) and dysosmia (as ''a fetid smell''). She also experienced unexpected episodes of flushing, feelings of fear, and hyperventilation that lasted a couple of minutes. Her medical history was unremarkable except for type 1 diabetes. Episodes of hyperventilation were initially interpreted as panic attacks and treated with a selective serotonin reuptake inhibitor. However, they became more frequent over the following 3 weeks. The patient became confused and disoriented. She eventually presented myoclonus, nystagmus and fever. Finally, focal dyscognitive seizures evolved into non convulsive status epilepticus.
CSF analysis showed mild pleocytosis with slightly elevated protein. EEG disclosed rhythmical 8-Hz activity with evolution into a slower 4-Hz activity starting in the left frontotemporal region that then generalized. Those abnormalities were correlated with episodes of hyperventilation associated with myoclonic jerks involving the right side of the mouth. Periodic epileptiform discharges as well as multiple seizures were recorded on continuous video-EEG. Brain MRI showed multifocal T2/FLAIR hyperintensities mostly involving the right temporal lobe, but also both frontal lobes and the parasagittal area. Routine haematological and biochemical analyses, as well as serological testing for systemic autoimmune and infectious disorders were unremarkable. Onconeuronal antibodies and those against cell surface antigens (NMDAR, LGI1, CASPR2, AMPAR and GABA B R) were Purpose: Autoimmune encephalitis is an inflammatory disorder of the brain that may be associated with different neuronal antibodies. Recently, an increasing number of valuable autoantibodies have been identified, including GABA A R antibodies, which appear to be associated with a severe form of encephalitis with refractory status epilepticus. We report here on a patient with encephalitis associated with GAD65 and GABA A R antibodies, an entity that remains an understudied topic, with an unanticipated clinical presentation and we describe the longitudinal follow-up. Methods: We report a case of encephalitis associated with GAD65 and GABA A R antibodies; we describe clinical and paraclinical features and the longitudinal follow-up. Results: Our case presented with dysgueusia, dysosmia and episodes of hyperventilation that evolved into a refractory status epilepticus. Multiple anticonvulsant drugs were required. An aggressive immunotherapy was associated with a relative favorable outcome, in regard of epilepsy and cognitive functions. However, a relapse occurred and a full recovery was not observed at the last follow-up visit. There was no correlation between GAD65 antibodies titers and disease activity. Conclusion: Autoimmune encephalitis associated with GABA A R and GAD65 antibodies might be a severe and refractory disease. The appropriate treatment is currently unknown for those patients.
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negative. Whole-body CT-scan and PET-FDG did not reveal any malignancy. GAD65 and GABA A R (strong positive) [2] antibodies were positive in CSF (courtesy of Professor Angela Vincent). Given the high clinical suspicion for autoimmune encephalitis, therapy was rapidly initiated using intravenous methylprednisolone, but no improvement was observed. Intravenous immunoglobulin was also administered. Concomitantly, intensive anticonvulsive drug therapy was started. The patient was sedated and mechanically ventilated (receiving a gradual combination of intravenous propofol that was eventually substituted for midazolam, ketamine, phenytoin, topiramate, levetiracetam and lacosamide). Continuous EEG showed a complete resolution of electrographic seizures after 11 days. Consciousness gradually improved; she left the intensive care unit 3 weeks after the beginning of treatment.
After the acute phase, a long and slow rehabilitation began. Anticonvulsants were slowly tapered. Brain MRI control showed improvement of T2/FLAIR hyperintensity with left hippocampal atrophy and sclerosis. On the third month of hospitalization, psychiatric problems became predominant, starting with anxiety. Ultimately, she became psychotic with paranoid delusions and antipsychotic drugs were required. She also developed rigidity in her right arm with rest and action tremors. Multidirectional nystagmus and significantly reduced psychomotor activity were also noted. Consequently, rituximab was introduced. Due to the fact that little improvement was seen after some weeks, mycophenolate mofetil was subsequently added. In total, the hospitalization lasted 5 months. On an ambulatory basis, a lumbar puncture was conducted and showed positive GAD65 antibodies at 517 U/ml (1857 U/ml in serum). Significant improvement was noted; she was autonomous and seizure-free.
At 13 months, an acute relapse of dysgueusia occurred. It also presented with headache, recurrent vomiting and increased tremor. This was associated with a significant weight loss; enteral tube feeding was required. At that time, brain MRI was unchanged and continuous EEG did not show any epileptiform abnormality. GAD65 antibodies were slightly lower than previously (362 U/ml in CSF, 1517 U/ml in serum) and GABA A R antibodies were still positive (strong positive in serum, moderate positive in CSF) [2] . A further dose of rituximab was not indicated. Tacrolimus was then introduced. Mycophenolate mofetil and topiramate (due to potential loss of appetite as a side effect) were progressively tapered.
At last follow-up (about 21 months after initial presentation), she was autonomous and free of seizures, psychotic symptoms and dysgueusia. A careful decrease of anticonvulsants and a long-term treatment with tacrolimus were planned (Fig. 1) .
Discussion
The case of a young female patient with autoimmune encephalitis associated with GABA A R and GAD65 antibodies is described. The clinical presentation was unanticipated and followup exposed a severe and ''relapsing-remitting'' course.
At the beginning, the patient presented with dysgueusia and dysosmia. To our knowledge, this had been reported in one other case of autoimmune encephalitis with GABA A R antibodies [1] and in a young boy with a diagnosis of limbic encephalitis associated with GAD65 antibodies [3] . Initially, epileptic aetiology was attributed to these manifestations due to the concurrence of episodes of hyperventilation and the fact that delayed antiepileptic treatment led to status epilepticus. However, there was no correlation at continuous EEG when she was admitted for a relapse of dysgueusia and a decrease of anticonvulsants did not exacerbate the problem. Thus, it could also be a ''purely limbic'' manifestation.
Treatment of status epilepticus of our patient involved multiple anticonvulsant drugs, including pharmacological induced coma and the use of immunotherapy. This refractory state could be explained by GABA A R antibodies' positivity: inhibitory neurotransmission is mostly mediated by ligand-gated GABA A receptors and antagonism of these receptors induces seizures [4] . Overall, an aggressive immunotherapy with steroids, intravenous immunoglobulin, rituximab, mycophenolate mofetil and tacrolimus was associated with a relative favourable outcome in regards to epilepsy and cognitive functions, but was however associated with relapse. Indeed, 21 months after the onset of symptoms, a full recovery was not observed and relapse could occur again, particularly with discontinuation of immunosuppressants. The appropriate duration of the treatment is currently unknown for these patients.
Here, the testing was not limited at GAD65 antibodies, which are antibodies for intracellular antigens, but included testing of neuronal cell-surface antibodies which are more thought to be pathogenic [1] . Interestingly, there was no correlation between GAD65 antibodies titers and disease activity in this case. Indeed, titers were lower during the relapse than on an ambulatory basis. Finally, the concurrence of positive GAD65 antibodies and neuronal cell-surface antibodies such as GABA A R might indicate a severe and refractory disease, as for this patient.
